Target Ovarian Cancer's medical research programme funds ovarian cancer specific research across the whole of the UK. We fund innovative research that will benefit the largest proportion of women with ovarian cancer in the shortest timeframe. Our research strategy sets out our specific priorities for advancing research to benefit women with ovarian cancer.
- Funding for ovarian cancer research
- Our priorities
- New targeted treatments and optimising existing treatments
- Our principles
- How we fund research
- Research governance
- Research support and advocacy
Only 35 per cent of women diagnosed with ovarian cancer in the UK survive their disease for ten years or more. Survival from ovarian cancer is much worse than for many other cancers, due to late diagnosis and a lack of effective treatment options. Research into new treatments lags significantly behind other cancer types. Funding is urgently required to support exciting new ideas, driving these to become the new treatments that are so desperately needed.
In a short period of time, Target Ovarian Cancer has developed a reputation as a funder of high quality research. We have already committed over £850,000 to seven outstanding projects, selected through open competition.
In recent years there has been a worrying decline in the UK’s spend on ovarian cancer research and this needs to be reversed. Public spend on ovarian cancer research has decreased by 39 per cent, from £13.3m in 2011 to £8.1m in 20151. Therefore, there is an urgent need for Target Ovarian Cancer to boost substantially the amount it spends on research.
This strategy highlights the areas of research that are vital to improve outcomes for patients. In seeking the greatest benefit from the limited resources available to Target Ovarian Cancer, our main priority will be to develop new treatments. However, we will work in partnership with other organisations to advance research into all priority areas.
- Prevention: Reduce the incidence of ovarian cancer
- Improving early diagnosis: Ensure that ovarian cancer is diagnosed earlier and accurately
- Finding new treatments: Improve survival by developing new targeted treatments and optimising existing treatments
- Support for women: Provide a better quality of life for women living with ovarian cancer
Target Ovarian Cancer’s primary objective is to accelerate research aimed at optimising and developing more effective and less toxic treatments for ovarian cancer, with a special focus on treatments that will improve overall survival. Surgery and chemotherapy are most widely used however very few new treatments have been developed in the last 15 years, or are currently in development.
Many important challenges need to be overcome to improve treatments for patients. Some examples are provided below, however Target Ovarian Cancer will consider support for any research of relevance to optimising or developing new treatments.
- Identify new drug targets within subtypes of ovarian cancer and develop new targeted treatments
- Understand why tumours develop resistance to therapies, developing strategies to prevent and overcome resistance
- Develop new immunologic approaches to treating ovarian cancer
- Understand the effectiveness of existing drugs against different tumour subtypes
- Understand the effectiveness of specific drug combinations in subtypes
- Research to predict which patients will benefit from chemotherapy
- Develop appropriate treatments for older patients
- Identify prognostic markers that indicate response to treatment
- Develop robust surgical trials to validate new technologies and optimise treatments
Five principles underpin our research strategy:
- access to funding for all UK researchers with an interest in ovarian cancer through open competition
- the importance of multidisciplinary collaboration between researchers to accelerate progress
- non-duplication of existing efforts
- clear focus on outcomes and impact
- independent peer review to determine and monitor all funding decisions
Translational research lies at the heart of Target Ovarian Cancer’s strategy. This is the approach whereby scientists and clinicians work together closely, sharing insight and ideas on what causes ovarian cancer and how best to treat it. We will support high quality research and build capacity by supporting innovative projects and the development of early career researchers.
The key mechanism for delivering research funding will be through awarding Translational Project Grants. In the future, we will also provide support for early career researchers through Translational Research Fellowships and support innovative ideas and new collaborations through Network/Consortium Development Grants.
Target Ovarian Cancer’s funding schemes embrace multidisciplinary collaboration between researchers, which is vital to tackling the complex challenges behind the disease.
Support for research of the highest quality is ensured through our Scientific Advisory Board (SAB), which includes leading UK and international ovarian cancer specialists. The SAB provides expert advice to the Target Ovarian Cancer Board of Trustees on:
- development of the research strategy and grant giving programme
- identifying external reviewers for grant applications
- assessing external reviews and final recommendations on grant applications
- annual review of funded projects
In addition to best practice in external peer review, and in accordance with its commitment to ensure that the interests of women with ovarian cancer drive the charity’s work, Target Ovarian Cancer’s research advocates work alongside the Scientific Advisory Board to reach funding decisions.
Target Ovarian Cancer is a member of the Association of Medical Research Charities (AMRC). Our peer review process follows best-practice guidance as set out by the AMRC and our funding meets the regulations of the Charity Research Support Fund (CSRF).
Grant application guidelines, forms and terms and conditions as well as details of the Scientific Advisory Board and grant review are available. All applicants are given anonymised feedback from reviewers on notification of funding decisions. Target Ovarian Cancer is committed to disseminating widely the outcomes of its funded research in peer-reviewed journals, research meetings and through our own website.
Target Ovarian Cancer further helps accelerate progress towards new treatments for ovarian cancer by advocating at a national level for the most favourable environment for research (increased funding, streamlined regulation and governance, approvals of new therapies etc) and by enabling women with ovarian cancer, where they wish, to take a more active role in the design of clinical trials and participation therein. The interactive Target Ovarian Cancer Clinical Trials Information Centre supports this intent. We support the work of NCRI Gynaecological Cancer Clinical Studies Group and the Ovary Sub-Group on an as-needed basis.
Our research strategy has been developed following a comprehensive review of the major challenges that need to be overcome to improve outcomes for patients. The review was informed by a wide range of expert opinions, including many senior scientists, clinicians and people affected by ovarian cancer.
We believe that there is an overwhelming case to increase the level of funding for ovarian cancer research. If a substantial increase in funding can be realised, rapid improvements to the treatment of ovarian cancer are possible, using new strategies that incorporate a more precise approach to treating disease.
1. NCRI Cancer Research Database; www.ncri.org.uk/what-we-do/research-database